[go: up one dir, main page]

FI20040531A7 - Insuliiniresistenttien tilojen hoitaminen ja diagnosointi - Google Patents

Insuliiniresistenttien tilojen hoitaminen ja diagnosointi Download PDF

Info

Publication number
FI20040531A7
FI20040531A7 FI20040531A FI20040531A FI20040531A7 FI 20040531 A7 FI20040531 A7 FI 20040531A7 FI 20040531 A FI20040531 A FI 20040531A FI 20040531 A FI20040531 A FI 20040531A FI 20040531 A7 FI20040531 A7 FI 20040531A7
Authority
FI
Finland
Prior art keywords
treating
resistant conditions
diagnosing insulin
diagnosing
insulin
Prior art date
Application number
FI20040531A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Venita I Dealmeida
Timothy A Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI20040531A7 publication Critical patent/FI20040531A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
FI20040531A 2001-10-15 2002-10-15 Insuliiniresistenttien tilojen hoitaminen ja diagnosointi FI20040531A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32994701P 2001-10-15 2001-10-15
PCT/US2002/032874 WO2003032810A2 (fr) 2001-10-15 2002-10-15 Diagnostic et traitement de pathologies resistant a l'insuline

Publications (1)

Publication Number Publication Date
FI20040531A7 true FI20040531A7 (fi) 2004-04-14

Family

ID=23287695

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20040531A FI20040531A7 (fi) 2001-10-15 2002-10-15 Insuliiniresistenttien tilojen hoitaminen ja diagnosointi

Country Status (16)

Country Link
US (3) US20030100504A1 (fr)
JP (1) JP2005506342A (fr)
CN (1) CN1571675A (fr)
AT (1) AT500646A1 (fr)
CA (1) CA2461818A1 (fr)
CZ (1) CZ2004564A3 (fr)
DE (1) DE10297331T5 (fr)
DK (1) DK200400777A (fr)
ES (1) ES2304072B1 (fr)
FI (1) FI20040531A7 (fr)
GB (1) GB2395903B (fr)
IL (1) IL161198A0 (fr)
LU (1) LU91070B1 (fr)
MX (1) MXPA04003536A (fr)
SE (2) SE528775C2 (fr)
WO (1) WO2003032810A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1680112E (pt) * 2003-10-29 2011-03-24 Genzyme Corp N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina
WO2006010534A1 (fr) * 2004-07-28 2006-02-02 F.Hoffmann-La Roche Ag Dickkopf 3 en tant que cible / marqueur de la defaillance des cellules beta
WO2006061717A2 (fr) * 2004-12-09 2006-06-15 Neuro Therapeutics Ab Materiels et methodes lies aux ligands dickkopf et a la neurogenese
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
CN1963511B (zh) * 2005-11-11 2014-09-24 上海市肿瘤研究所 Dkk-1蛋白在癌症诊断中的应用
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
SG174891A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
JP7064452B2 (ja) * 2016-06-30 2022-05-10 ノボ・ノルデイスク・エー/エス インスリン計画アドヒアランスデータの分析のためのシステムおよび方法
CN115124424B (zh) * 2022-06-01 2024-04-05 重庆市食品药品检验检测研究院 非诺贝特半抗原及其制备方法、非诺贝特抗原、抗体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus

Also Published As

Publication number Publication date
ES2304072B1 (es) 2009-07-07
GB2395903A (en) 2004-06-09
HK1063280A1 (en) 2004-12-24
GB2395903B (en) 2005-08-31
LU91070B1 (en) 2004-04-15
CZ2004564A3 (cs) 2005-03-16
IL161198A0 (en) 2004-08-31
SE528775C2 (sv) 2007-02-13
WO2003032810A2 (fr) 2003-04-24
WO2003032810A3 (fr) 2004-06-17
SE0400961L (sv) 2004-04-14
DE10297331T5 (de) 2004-11-18
JP2005506342A (ja) 2005-03-03
CN1571675A (zh) 2005-01-26
AT500646A1 (de) 2006-02-15
GB0407486D0 (en) 2004-05-05
US20030100504A1 (en) 2003-05-29
ES2304072A1 (es) 2008-09-01
DK200400777A (da) 2004-05-14
US20060293239A1 (en) 2006-12-28
US20050170440A1 (en) 2005-08-04
CA2461818A1 (fr) 2003-04-24
MXPA04003536A (es) 2004-07-23
SE0602516L (sv) 2006-11-27
SE0400961D0 (sv) 2004-04-14

Similar Documents

Publication Publication Date Title
DE60234652D1 (de) Verschleissteil und -anordnung
EP1298180A4 (fr) Composition hydrofuge et oleofuge
DE50213336D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
FI20011421L (fi) Menetelmä ja laite toiminnon toteuttamiseksi
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE60225367D1 (de) Ausatmungskassette
FI20000863A0 (fi) Uusi hoitomenetelmä
NO20035121D0 (no) Ny anvendelse
BR0210823B1 (pt) polia e conjunto de polia.
FI20011463L (fi) Turvavalojärjestely ja turvavalolaite
DE60221403D1 (de) Doppelstrom - verdichter
FI20002700L (fi) Hissi ja hissin vetopyörä
DE60227963D1 (de) Behandlungssystem
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
NO20013337L (no) Ny behandling
DE10197149T1 (de) Anti-Zusetz-Behandlungen
DE60114244D1 (de) Osteosynthesevorrichtung
DE60220799D1 (de) Hypoglykämisches mittel
NO20033919D0 (no) Ny anvendelse
FI20021780A7 (fi) Menetelmät ja laitteet järjestelmän käyttämiseksi
DE60136966D1 (de) Pflanzenstärkendes mittel
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
ATE354561T1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen
DE60219418T8 (de) Silanylphenole und -naphthole
DE60143766D1 (de) Dübel und verwendungsverfahren dafür

Legal Events

Date Code Title Description
MA Patent expired